MCID: OST122
MIFTS: 56

Osteogenesis Imperfecta, Type Iii malady

Categories: Genetic diseases, Rare diseases, Bone diseases, Fetal diseases, Oral diseases

Aliases & Classifications for Osteogenesis Imperfecta, Type Iii

About this section
Sources:
49OMIM, 11diseasecard, 68Wikipedia, 45NIH Rare Diseases, 47Novoseek, 51Orphanet, 67UniProtKB/Swiss-Prot, 24GTR, 65UMLS, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 36MeSH, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Osteogenesis Imperfecta, Type Iii:

Name: Osteogenesis Imperfecta, Type Iii 49
Osteogenesis Imperfecta Type Iii 68 45 67 65
Progressively Deforming Osteogenesis Imperfecta with Normal Sclerae 68 67
Progressive Deforming Osteogenesis Imperfecta 45 51
Severe Osteogenesis Imperfecta 45 51
Osteogenesis Imperfecta 3 67 24
Oi, Type Iii 47 67
 
Oi Type Iii 11 45
Oi Type 3 45 51
Osteogenesis Imperfecta, Progressively Deforming with Normal Sclerae 45
Osteogenesis Imperfecta Type 3 51
Progressively Deforming Oi 45
Oi-Iii 67
Oi3 67

Characteristics:

Orphanet epidemiological data:

51
progressive deforming osteogenesis imperfecta:
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal

HPO:

61
osteogenesis imperfecta, type iii:
Inheritance: autosomal recessive inheritance, autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 259420
Orphanet51 216812
ICD10 via Orphanet28 Q78.0
MESH via Orphanet37 C536044
UMLS via Orphanet66 C0268362
MedGen34 C0268362
MeSH36 D010013
UMLS65 C0268362

Summaries for Osteogenesis Imperfecta, Type Iii

About this section
NIH Rare Diseases:45 Osteogenesis imperfecta type iii (oi type iii) is a form of osteogenesis imperfecta, a group of genetic conditions that primarily affect the bones. in oi type iii, specifically, a diagnosis can often be made shortly after birth as fractures (broken bones) during the newborn period simply from handling the infant are common. other signs and symptoms vary significantly from person to person but may include severe bone fragility, bone malformations, short stature, dental problems (dentinogenesis imperfect), macrocephaly (unusually large head), hearing loss, and blue sclerae (whites of the eyes). most affected people are unable to walk without assistance. oi type iii is caused by changes (mutations) in the col1a1 or col1a2 genes and is inherited in an autosomal dominant manner. treatment is based on the signs and symptoms present in each person. last updated: 3/24/2016

MalaCards based summary: Osteogenesis Imperfecta, Type Iii, also known as osteogenesis imperfecta type iii, is related to progressively deforming osteogenesis imperfecta and congenital trigeminal anesthesia, and has symptoms including neonatal short-limb short stature, severe generalized osteoporosis and multiple prenatal fractures. An important gene associated with Osteogenesis Imperfecta, Type Iii is COL1A2 (Collagen Type I Alpha 2), and among its related pathways are VEGFR3 signaling in lymphatic endothelium and Inflammatory Response Pathway. Affiliated tissues include bone, eye and bone marrow, and related mouse phenotypes are adipose tissue and limbs/digits/tail.

UniProtKB/Swiss-Prot:67 Osteogenesis imperfecta 3: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI3 is characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera and dentinogenesis imperfecta.

Description from OMIM:49 259420

Related Diseases for Osteogenesis Imperfecta, Type Iii

About this section

Diseases in the Osteogenesis Imperfecta family:

Osteogenesis Imperfecta, Type Viii Osteogenesis Imperfecta, Type Vii
Osteogenesis Imperfecta, Type Xvii Osteogenesis Imperfecta, Type Iv
osteogenesis imperfecta, type iii Osteogenesis Imperfecta, Type Ii
Osteogenesis Imperfecta, Type Xiii Osteogenesis Imperfecta, Type Xiv
Osteogenesis Imperfecta, Type V Osteogenesis Imperfecta, Type Xvi
Osteogenesis Imperfecta, Type X Osteogenesis Imperfecta, Type Xv
Osteogenesis Imperfecta, Type Xii Osteogenesis Imperfecta, Type Ix
Osteogenesis Imperfecta, Type Vi Osteogenesis Imperfecta, Type Xi
Osteogenesis Imperfecta, Type I Bmp1-Related Osteogenesis Imperfecta
Crtap-Related Osteogenesis Imperfecta Fkbp10-Related Osteogenesis Imperfecta
Ifitm5-Related Osteogenesis Imperfecta Lepre1-Related Osteogenesis Imperfecta
Ppib-Related Osteogenesis Imperfecta Serpinf1-Related Osteogenesis Imperfecta
Serpinh1-Related Osteogenesis Imperfecta Sp7-Related Osteogenesis Imperfecta
Tmem38b-Related Osteogenesis Imperfecta Sparc-Related Osteogenesis Imperfecta
Wnt1-Related Osteogenesis Imperfecta

Diseases related to Osteogenesis Imperfecta, Type Iii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 77)
idRelated DiseaseScoreTop Affiliating Genes
1progressively deforming osteogenesis imperfecta11.7
2congenital trigeminal anesthesia10.4COL1A1, COL1A2
3col4a1-related disorders10.4COL1A1, COL1A2
4idiopathic linear interstitial keratitis10.4COL1A1, COL1A2
5eif4g1-related parkinson disease10.4COL1A1, COL1A2
6osteogenesis imperfecta, type iv10.4COL1A1, COL1A2
7prok2-related isolated gonadotropin-releasing hormone deficiency10.4COL1A2, SERPINF1
8autosomal dominant microcephaly10.4COL1A1, COL1A2
9cerebritis10.4
10endotheliitis10.4
11anodontia10.3BGLAP, COL1A2
12lymph node adenoid cystic carcinoma10.3CD36, COL1A1, COL1A2
13ehlers-danlos syndrome, classic type10.3CD36, COL1A1, COL1A2
14mental retardation, autosomal recessive 3510.3COL1A1, COL1A2
15osteogenesis imperfecta levin type10.2BGLAP, CD36
16anterior cruciate ligament tears10.2BGLAP, COL1A1, COL1A2
17ankylosis10.2BGLAP, COL1A1, COL1A2
18aortic aneurysm, familial abdominal, 410.2FKBP10, SERPINF1
19darier disease10.2COL1A1, COL1A2
20osteogenesis imperfecta, type vii10.2CD36, CRTAP
21hepatocellular carcinoma10.2
22asthma10.2
23breast cancer10.2
24alzheimer disease10.2
25anal fistula10.2
26gingival recession10.2
27lymphomatoid granulomatosis10.2
28osteochondrosis10.2
29spinal cord injury10.2
30familial adenomatous polyposis10.2
31lymphoma10.2
32cerebral artery occlusion10.2
33gingivitis10.2
34periodontal disease10.2
35tuberculosis10.2
36peanut allergy10.2
37poliomyelitis10.2
38periodontitis10.2
39amyloidosis10.2
40renal tuberculosis10.2
41pontocerebellar hypoplasia, type 2e10.2FKBP10, SERPINF1
42marcus gunn phenomenon10.2BGLAP, CD36
43dicrocoeliasis10.2COL1A1, COL1A2
44obesity10.1
45renal cell carcinoma10.1
46insulin-like growth factor i10.1
47angina pectoris10.1
48peyronie's disease10.1
49gastric cancer10.1
50hepatitis10.1

Graphical network of the top 20 diseases related to Osteogenesis Imperfecta, Type Iii:



Diseases related to osteogenesis imperfecta, type iii

Symptoms for Osteogenesis Imperfecta, Type Iii

About this section

Symptoms by clinical synopsis from OMIM:

259420

Clinical features from OMIM:

259420

HPO human phenotypes related to Osteogenesis Imperfecta, Type Iii:

(show all 25)
id Description Frequency HPO Source Accession
1 neonatal short-limb short stature HP:0008921
2 severe generalized osteoporosis HP:0005897
3 multiple prenatal fractures HP:0005855
4 basilar impression HP:0005758
5 decreased calvarial ossification HP:0005474
6 biconcave vertebral bodies HP:0004586
7 protrusio acetabuli HP:0003179
8 slender long bone HP:0003100
9 bowing of limbs due to multiple fractures HP:0003023
10 tibial bowing HP:0002982
11 kyphosis HP:0002808
12 recurrent fractures HP:0002757
13 platybasia HP:0002691
14 scoliosis HP:0002650
15 wormian bones HP:0002645
16 pulmonary hypertension HP:0002092
17 frontal bossing HP:0002007
18 abnormality of the thorax HP:0000765
19 abnormality of the nervous system HP:0000707
20 dentinogenesis imperfecta HP:0000703
21 blue sclerae HP:0000592
22 hearing impairment HP:0000365
23 micrognathia HP:0000347
24 triangular face HP:0000325
25 wide anterior fontanel HP:0000260

Drugs & Therapeutics for Osteogenesis Imperfecta, Type Iii

About this section

Drugs for Osteogenesis Imperfecta, Type Iii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PamidronateapprovedPhase 34340391-99-94674
Synonyms:
(3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID
(3-Amino-1-hydroxypropylidene)bisphosphonic acid
(3-Amino-1-hydroxypropylidene)diphosphonic acid
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
(3-amino-1-hydroxypropylidene)-1,1-biphosphonate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate
1-hydroxy-3-aminopropane-1,1-diphosphonic acid
3-Amino-1-hydroxypropylidene-1,1-diphosphonate
40391-99-9
57248-88-1
57248-88-1 (di-hydrochloride salt)
AC1L1IP4
AHPrBP
AKOS003599275
APD
Acide pamidronique
Acide pamidronique [INN-French]
Acido pamidronico
Acido pamidronico [INN-Spanish]
Acidum pamidronicum
Acidum pamidronicum [INN-Latin]
Amidronate
Aminomux
Aredia
BIDD:GT0538
Bisphosphonate 6
C019248
C07395
C3H11NO7P2
 
CHEMBL834
CID4674
ChemDiv1_025240
D07281
DB00282
EINECS 254-905-2
HMS2090C13
HMS658L06
HSCI1_000312
I14-2407
LS-174826
MolPort-002-131-054
NCGC00159433-02
NCGC00159433-03
Novartis brand of pamidronate disodium salt
PAMIDRONATE DISODIUM
PAMIDRONIC ACID
Pamidronate Disodium
Pamidronic acid
Pamidronic acid (INN)
Pamidronic acid [INN:BAN]
Ribodroat
Ribodroat (TN)
STOCK1N-12562
UNII-OYY3447OMC
amino-1-hydroxypropane-1,1-diphosphonate
aminohydroxypropylidene diphosphonate
aminopropanehydroxydiphosphonate
pamidronate
pamidronate calcium
pamidronate monosodium
2DiphosphonatesPhase 3, Phase 2381
3Bone Density Conservation AgentsPhase 3, Phase 22600
4HormonesPhase 311748
5
Zoledronic acidPhase 3, Phase 2286118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
 
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
6Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 39988
7Hormone AntagonistsPhase 310002
8
Busulfanapproved, investigationalPhase 150655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
9
Cyclophosphamideapproved, investigationalPhase 1264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
10CyclosporinsPhase 1873

Interventional clinical trials:

idNameStatusNCT IDPhase
1An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis ImperfectaCompletedNCT00982124Phase 3
2Pamidronate to Treat Osteogenesis Imperfecta in ChildrenCompletedNCT00005901Phase 3
3Growth Hormone Therapy in Osteogenesis ImperfectaActive, not recruitingNCT00001305Phase 3
4Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis ImperfectaCompletedNCT00131118Phase 2
5Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis ImperfectaCompletedNCT01061099Phase 1
6Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow TransplantationCompletedNCT00705120Phase 1
7Evaluation and Intervention for the Effects of Osteogenesis ImperfectaRecruitingNCT00001594

Search NIH Clinical Center for Osteogenesis Imperfecta, Type Iii

Genetic Tests for Osteogenesis Imperfecta, Type Iii

About this section

Anatomical Context for Osteogenesis Imperfecta, Type Iii

About this section

MalaCards organs/tissues related to Osteogenesis Imperfecta, Type Iii:

33
Bone, Eye, Bone marrow, B cells, Prostate, Lung, T cells

Animal Models for Osteogenesis Imperfecta, Type Iii or affiliated genes

About this section

MGI Mouse Phenotypes related to Osteogenesis Imperfecta, Type Iii:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.3BMP1, CD36, COL1A1, COL1A2, CREB3L1, P3H1
2MP:00053718.0BMP1, COL1A1, COL1A2, CREB3L1, FKBP10, P3H1
3MP:00053827.8BMP1, COL1A1, FKBP10, PPIB, SERPINH1, WNT1
4MP:00053697.8BMP1, CD36, COL1A1, COL1A2, P3H1, WNT1
5MP:00053857.5BMP1, CD36, COL1A1, COL1A2, FKBP10, SERPINF1
6MP:00053786.5BMP1, CD36, COL1A1, COL1A2, CREB3L1, CRTAP
7MP:00053905.5BMP1, CD36, COL1A1, COL1A2, CREB3L1, CRTAP

Publications for Osteogenesis Imperfecta, Type Iii

About this section

Articles related to Osteogenesis Imperfecta, Type Iii:

(show all 29)
idTitleAuthorsYear
1
Diagnostic accuracy and patient acceptance of MRI in children with suspected appendicitis. (24135892)
2013
2
The neuropsychological profile of infantile Duchenne muscular dystrophy. (21999586)
2011
3
Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma]. (21518495)
2011
4
Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. (20617557)
2010
5
Cutting edge: association with I kappa B kinase beta regulates the subcellular localization of Homer3. (20693425)
2010
6
Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. (19707406)
2009
7
PAK is required for the disruption of E-cadherin adhesion by the small GTPase Rac. (18319303)
2008
8
No seasonal variation in the onset of symptoms of 445 patients with Wegener's granulomatosis. (18512707)
2008
9
Analysis of variation in NF-kappaB genes and expression levels of NF-kappaB-regulated molecules. (18466468)
2007
10
Relationship of cardiovascular risk factors and serum ferritin with C-reactive protein. (17174735)
2007
11
Analysis of coding-polymorphisms in NOTCH-related genes reveals NUMBL poly-glutamine repeat to be associated with schizophrenia in Brazilian and Danish subjects. (16899352)
2006
12
Placental site trophoblastic tumor originating in a tubal ectopic pregnancy. (16423444)
2006
13
Antiangiogenic properties of gold nanoparticles. (15867256)
2005
14
Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. (15257137)
2004
15
Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma. (15254691)
2004
16
A case of anhidrotic ectodermal dysplasia diagnosed during investigation of asthmatic attack]. (15500155)
2004
17
Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. (13130504)
2003
18
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. (11751490)
2001
19
Up-regulation of a fibroblast growth factor binding protein in children with renal diseases. (11318942)
2001
20
Aldolase]. (11797371)
2001
21
Identification of a renal-specific oxido-reductase in newborn diabetic mice. (10944187)
2000
22
Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. (9809035)
1998
23
Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. (8615058)
1995
24
Recombinant human erythropoietin in the treatment of anemia of prematurity. (8540930)
1995
25
Hemifacial spasm in childhood and adolescence. (7596501)
1995
26
The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer. (7512277)
1994
27
Extracorporeal shock wave lithotripsy in a patient with hemophilia A. A case report]. (8121121)
1994
28
Immunomodulation of human T cell responses with receptor selective enkephalins. (8384598)
1993
29
Rhabdomyosarcoma in Roberts syndrome. (3349442)
1988

Variations for Osteogenesis Imperfecta, Type Iii

About this section

UniProtKB/Swiss-Prot genetic disease variations for Osteogenesis Imperfecta, Type Iii:

67 (show all 41)
id Symbol AA change Variation ID SNP ID
1COL1A1p.Gly332ArgVAR_001650
2COL1A1p.Gly350ArgVAR_001651
3COL1A1p.Gly530SerVAR_001666
4COL1A1p.Gly593CysVAR_001673
5COL1A1p.Gly593SerVAR_001674
6COL1A1p.Gly704CysVAR_001678
7COL1A1p.Gly719SerVAR_001680
8COL1A1p.Gly767SerVAR_001686
9COL1A1p.Gly821SerVAR_001690
10COL1A1p.Gly884SerVAR_001697
11COL1A1p.Gly1022SerVAR_001702
12COL1A1p.Gly1040SerVAR_001705
13COL1A1p.Gly1049SerVAR_001708
14COL1A1p.Gly1058SerVAR_001709
15COL1A1p.Gly1076SerVAR_001713
16COL1A1p.Gly1151SerVAR_001722
17COL1A1p.Gly1187SerVAR_001729
18COL1A1p.Leu1464ProVAR_001737
19COL1A1p.Gly866SerVAR_008118
20COL1A1p.Gly203ValVAR_063295
21COL1A2p.Gly337CysVAR_001857
22COL1A2p.Gly337SerVAR_001858
23COL1A2p.Gly349CysVAR_001860
24COL1A2p.Gly460SerVAR_001863
25COL1A2p.Gly517ArgVAR_001865
26COL1A2p.Gly676ValVAR_001875
27COL1A2p.Gly778SerVAR_001884
28COL1A2p.Gly892AspVAR_001892
29COL1A2p.Gly949SerVAR_001894
30COL1A2p.Gly1012SerVAR_001897
31COL1A2p.Gly1096AlaVAR_001901
32COL1A2p.Thr1148ProVAR_001904rs1800250
33COL1A2p.Gly331AspVAR_008119
34COL1A2p.Gly973ValVAR_008120
35COL1A2p.Gly358SerVAR_063352
36COL1A2p.Gly676AspVAR_063361
37COL1A2p.Gly820SerVAR_063370
38COL1A2p.Gly835CysVAR_063371
39COL1A2p.Gly856ArgVAR_063372
40COL1A2p.Gly991ValVAR_063377
41COL1A2p.Gly1087AspVAR_063381

Clinvar genetic disease variations for Osteogenesis Imperfecta, Type Iii:

5 (show all 25)
id Gene Variation Type Significance SNP ID Assembly Location
1COL1A2NM_000089.3(COL1A2): c.4001_4004delATAA (p.Asn1334Serfs)deletionPathogenicrs72659345GRCh37Chr 7, 94059605: 94059608
2COL1A2NM_000089.3(COL1A2): c.775G> T (p.Gly259Cys)single nucleotide variantPathogenicrs121912905GRCh37Chr 7, 94038118: 94038118
3COL1A2NM_000089.3(COL1A2): c.1757G> T (p.Gly586Val)single nucleotide variantPathogenicrs121912907GRCh37Chr 7, 94044575: 94044575
4COL1A2COL1A2, VAL255DELdeletionPathogenic
5COL1A2NM_000089.3(COL1A2): c.2575G> A (p.Gly859Ser)single nucleotide variantPathogenicrs72658200GRCh37Chr 7, 94053657: 94053657
6COL1A2NM_000089.3(COL1A2): c.3017G> C (p.Gly1006Ala)single nucleotide variantPathogenicrs121912911GRCh37Chr 7, 94055754: 94055754
7COL1A2NM_000089.3(COL1A2): c.2251G> A (p.Gly751Ser)single nucleotide variantPathogenicrs72658176GRCh37Chr 7, 94049916: 94049916
8COL1A2NM_000089.3(COL1A2): c.1099G> T (p.Gly367Trp)single nucleotide variantPathogenicrs72656402GRCh37Chr 7, 94039741: 94039741
9COL1A2NM_000089.3(COL1A2): c.3269G> A (p.Gly1090Asp)single nucleotide variantPathogenicrs267606742GRCh37Chr 7, 94056940: 94056940
10COL1A2NM_000089.3(COL1A2): c.3295G> A (p.Gly1099Arg)single nucleotide variantPathogenicrs72659338GRCh37Chr 7, 94056966: 94056966
11COL1A1NM_000088.3(COL1A1): c.2110G> T (p.Gly704Cys)single nucleotide variantPathogenicrs67368147GRCh37Chr 17, 48269166: 48269166
12COL1A1NM_000088.3(COL1A1): c.3064G> A (p.Gly1022Ser)single nucleotide variantPathogenicrs66523073GRCh37Chr 17, 48266138: 48266138
13COL1A1COL1A1, EX22DELdeletionPathogenic
14COL1A1NM_000088.3(COL1A1): c.994G> A (p.Gly332Arg)single nucleotide variantPathogenicrs72645357GRCh37Chr 17, 48273524: 48273524
15COL1A1NM_000088.3(COL1A1): c.1588G> A (p.Gly530Ser)single nucleotide variantPathogenicrs67682641GRCh37Chr 17, 48271736: 48271736
16COL1A1NM_000088.3(COL1A1): c.3118G> A (p.Gly1040Ser)single nucleotide variantPathogenicrs72653178GRCh37Chr 17, 48265980: 48265980
17COL1A1NM_000088.3(COL1A1): c.2515G> A (p.Gly839Ser)single nucleotide variantPathogenicrs72653131GRCh37Chr 17, 48267406: 48267406
18COL1A1NM_000088.3(COL1A1): c.4391T> C (p.Leu1464Pro)single nucleotide variantPathogenicrs72656353GRCh37Chr 17, 48262867: 48262867
19COL1A1COL1A1, 562-BP DELdeletionPathogenic
20COL1A1NM_000088.3(COL1A1): c.761G> A (p.Gly254Glu)single nucleotide variantPathogenicrs72645320GRCh37Chr 17, 48274414: 48274414
21COL1A1NM_000088.3(COL1A1): c.959G> A (p.Gly320Asp)single nucleotide variantLikely pathogenicrs72645353GRCh37Chr 17, 48273559: 48273559
22COL1A2NM_000089.3(COL1A2): c.1971+1G> Asingle nucleotide variantPathogenicrs72658151GRCh37Chr 7, 94047144: 94047144
23COL1A2NM_000089.3(COL1A2): c.2099G> A (p.Gly700Asp)single nucleotide variantPathogenicrs72658161GRCh38Chr 7, 94420252: 94420252
24COL1A2NM_000089.3(COL1A2): c.3034G> A (p.Gly1012Ser)single nucleotide variantLikely pathogenicrs72659319GRCh38Chr 7, 94426459: 94426459
25COL1A2NM_000089.3(COL1A2): c.2957C> T (p.Pro986Leu)single nucleotide variantLikely pathogenicrs768171831GRCh37Chr 7, 94055323: 94055323

Expression for genes affiliated with Osteogenesis Imperfecta, Type Iii

About this section
Search GEO for disease gene expression data for Osteogenesis Imperfecta, Type Iii.

Pathways for genes affiliated with Osteogenesis Imperfecta, Type Iii

About this section

GO Terms for genes affiliated with Osteogenesis Imperfecta, Type Iii

About this section

Cellular components related to Osteogenesis Imperfecta, Type Iii according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1collagen type I trimerGO:000558410.0COL1A1, COL1A2
2endoplasmic reticulumGO:00057839.2COL1A1, CRTAP, SERPINH1
3endoplasmic reticulum lumenGO:00057888.7BGLAP, PPIB, WNT1

Biological processes related to Osteogenesis Imperfecta, Type Iii according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1protein peptidyl-prolyl isomerizationGO:000041310.3FKBP10, PPIB
2collagen biosynthetic processGO:003296410.2COL1A1, SERPINH1
3collagen catabolic processGO:003057410.0COL1A1, COL1A2
4cellular response to amino acid stimulusGO:00712309.9COL1A1, COL1A2
5skin morphogenesisGO:00435899.7COL1A1, COL1A2
6platelet activationGO:00301689.6CD36, COL1A1, COL1A2
7blood coagulationGO:00075969.6CD36, COL1A1, COL1A2
8ossificationGO:00015039.5BGLAP, BMP1, COL1A1
9extracellular matrix disassemblyGO:00226179.4BMP1, COL1A1, COL1A2
10bone developmentGO:00603489.2BGLAP, PPIB, WNT1

Sources for Osteogenesis Imperfecta, Type Iii

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet